KFDA announces safety information of pergolide products
Published: 2007-04-04 06:56:00
Updated: 2007-04-04 06:56:00
The Korea Food and Drug Administration issued a warning letter of the prescribing information for pergolide mesylate (Permax) to inform healthcare professionals of reports of cardiac valvulopathy involving one or more valves in patients receiving pergolide therapy
The U.S. Food and Drug Admini...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
